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Characterization of Protein Involved in Hemolysis Expressed by
Sneathia amnii, a Pathogen of the Female Urogenital Tract
Gabriella L. Gentile, Lizette I. Carrasco, Amy Stanford, Kimberly K. Jefferson, PhD.
Department of Microbiology and Immunology, School of Medicine, Virginia Commonwealth University, Richmond VA

What role does SaFHA play in S. amnii?

Sneathia amnii is a poorly characterized gram-negative anaerobe
that commonly colonizes the vagina. It has been linked to many
obstetric disorders, including preterm labor, preeclampsia, and
chorioamnionitis. S. amnii lyses human red blood cells, and we aimed
to identify the hemolysin. We identified two genes that appear to
encode transporter and effector components of a two-partner
secretion system. The putative effector, which we refer to as SaFHA,
contains a domain with amino acid similarity to the filamentous
hemagglutinin (FHA) of Bordetella pertussis and its predicted
structure suggests it may form a transmembrane channel or pore.
Thus, we hypothesized that SaFHA would be secreted by S. amnii
and that it would play a role in hemoglobbin release. To test this, a
portion of the gene encoding the SaFHA protein in S. amnii was
expressed in E. coli and used as an immunogen in rabbits. Western
analysis using anti-SaFHA revealed that the protein is secreted and
localizes to the bacterial surface. Pre-treatment of S. amnii with antiSaFHA blocked the hemolytic activity whereas antiserum against an
irrelevant protein had no effect. We partially purified SaFHA from S.
amnii using cation exchange chromatography and the partially
purified protein mediated hemoglobin release from human RBC,
supporting our hypothesis. Further characterization of SaFHA will
help provide more insight on the virulence of S. amnii, and perhaps
shed light on the etiology of Sneathia-associated vaginal conditions,
as well as future treatment options.

Bioinformatic analysis of Sn35 genome identified 2 genes with amino acid and structural similarity
to two proteins involved in two-partner type Vb secretion (Tps) system of B. pertussis.

B.
pertussis

FHA = Effector
• Outer membraneassociated
filamentous
hemagglutinin,
and an adhesin
FhaC =
Transporter
• β-pore-forming
protein, located in
the outer
membrane

SaFHA has a predicted pI of 9.4. Cation exchange was used to purify SaFHA from
outer membrane extracts of S. amnii.

S. amnii
250 kda
SaFHA = Effector

SaFHB =
Transporter

Fig. 2 Structural
comparison of
transporter proteins in
S.amnii and B.
pertussis. Left: FhaC
from B. Pertussis. Right:
SaFHB from S. amnii

Fig. 3 General model for two-partner
system (TPS) secretion. Effector (TpsA)
transporter (TpsB) proteins are synthesized
and translocated across the CM via the Sec
system. Transporter inserts itself into the
OM forming a β-barrel that mediates the
secretion of effector protein. Image adapted
from Mazar, et al. (2007).

Hypothesis

SaFHA antiserum, but not pre-immune serum or
antiserum against an irrelevant protein, blocks
hemolytic activity against human erythrocytes,
suggesting SaFHA is involved in hemolysis.

SaFHA is localized to the outer membrane of
S. amnii.

The FHA
homologue of S.
amnii plays a role
in the release of
hemoglobin from
human RBC.
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Fig. 1 (A) SEM micrograph of Sneathia
amnii morphology. (B) S. amnii consists of
long gram-negative rods and short rods and
cocci.
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Fig. 6 Purification of SaFHA
using cation exchange. OM
extracts were suspended in
20mM Tris pH8 + 0.5% Triton-X,
sonicated, and filter sterilized. The
OM was applied to a cation
exchange column, and passed
through a series of wash steps.
Western analysis was performed
on the flow through from each
wash step. 1). OM Before filtering,
2). OM After filtering, 3). OM
cation flow through, 4). Tris pH 8,
5). Tris pH 8 + 100mM NaCl, 6).
Tris pH8 + 200mM NaCl, 7). Tris
pH 8 + 500mM, 8). Tris pH 8 +
1M. SaFHA ~250 kDA.
Fig. 7 Hemolytic activity of SaFHA.
Purified SaFHA was added to human
erythrocytes at increasing
concentrations and allowed to incubate
for 2 hrs. at 37˚C. Remaining whole
cells were removed by centrifugation
and the amount of hemoglobin
released into the supernatant was
quantified by measuring absorbance at
OD450nm.

Scheme for Production of Isogenic saFHA Deletion Mutant
In order to characterize the role of the SaFHA in the lysis of
human red blood cells, an isogenic saFHA mutant of Sn35 will be
constructed through homologous recombination. This mutant
strain, in addition to purified protein (explained above), will be
used in adherence and hemolysis assays to assess the role of
SaFHA in adherence and hemolysis.
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Fig. 4 Western blot of outer membrane
fraction of Sn35. 1). 10-250kDa protein ladder,
2). Spent medium from first centrifugation step,
3). S. amnii fraction, 4). Post- French Press
pellet fraction, 5). Supernatant fraction from
ultracentrifuge, 6). Outer membrane fraction.
*SaFHA (~200 kDa) detected in lanes 3, 4, and
6. SaFHA ~250 kDA.

Fig. 5 Antiserum inhibition of Sn35 hemolytic
activity. S. amnii strain Sn35 was pre-treated with either
PBS, pre-immune rabbit serum, antiserum against
SaFHA, or antiserum against an irrelevant protein. An
erythrocyte lysis assay was performed by incubating
200µL of human erythrocytes with 50µL PBS (negative
control), 0.1% TWEEN 20 (positive control) or 106 pretreated bacteria for 2hr at 37˚C. The cells were removed
by centrifugation and the absorbance of the supernatant
at 450 nm was measured.

Fig. 8 Scheme for production of isogenic saFHA
deletion mutant. A small portion of the upstream and
downstream region of the gene remains intact, while the
middle is knocked out and replaced with a CAT antibiotic
resistance cassette, obtained from E. coli pKD3 plasmid.

Fig. 9 Agarose gel of
linearized DNA
f r a g m e n t ,
constructed through
SOE PCR. 1). 1 kb
DNA ladder, 2). SOE
PCR product.
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